Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2020 1
2021 2
2022 1
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Barratt J, et al. Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. Kidney Int. 2023. PMID: 36270561 Free article. Clinical Trial.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Belimumab, a useful alternative therapy in systemic lupus erythematosus serositis.
Salman-Monte TC, Carrión-Barberà I, Rodríguez García E. Salman-Monte TC, et al. Among authors: rodriguez garcia e. Med Clin (Barc). 2021 Sep 10;157(5):261-262. doi: 10.1016/j.medcli.2020.06.034. Epub 2020 Aug 15. Med Clin (Barc). 2021. PMID: 32807511 English, Spanish. No abstract available.
Role of C5aR1 and C5L2 Receptors in Ischemia-Reperfusion Injury.
Arias-Cabrales C, Rodriguez-Garcia E, Gimeno J, Benito D, Pérez-Sáez MJ, Redondo-Pachón D, Buxeda A, Burballa C, Crespo M, Riera M, Pascual J. Arias-Cabrales C, et al. Among authors: rodriguez garcia e. J Clin Med. 2021 Mar 2;10(5):974. doi: 10.3390/jcm10050974. J Clin Med. 2021. PMID: 33801177 Free PMC article.
Acute kidney injury, when to dialyze critically ill patients?
Rodríguez García E, Pascual Santos J. Rodríguez García E, et al. Nefrologia. 2017 Nov-Dec;37(6):563-566. doi: 10.1016/j.nefro.2016.12.002. Epub 2017 Oct 21. Nefrologia. 2017. PMID: 29031408 Free article. English, Spanish. No abstract available.
Extremely high levels of vancomycin can cause severe renal toxicity.
Barceló-Vidal J, Rodríguez-García E, Grau S. Barceló-Vidal J, et al. Among authors: rodriguez garcia e. Infect Drug Resist. 2018 Jul 30;11:1027-1030. doi: 10.2147/IDR.S171669. eCollection 2018. Infect Drug Resist. 2018. PMID: 30104890 Free PMC article.